{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:12:23Z","timestamp":1753877543129,"version":"3.41.2"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data have suggested that treatment with Paxlovid for acute COVID-19 decreases the incidence of Post-COVID Conditions (PCC); however, results are limited to specific age groups and populations. This analysis assessed the occurrence of PCC following receipt of Paxlovid among children and adults at risk for severe COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged \u2265 12 years with COVID-19 (defined by ICD-10 code, positive SARS-CoV-2 test, or Paxlovid prescription) and at increased risk for severe COVID-19 due to age, underlying conditions, or immune-suppressing medications, were identified in HealthVerity claims data. Eligible persons had an outpatient, telehealth, or emergency department encounter for COVID-19 between April 1 \u2013 August 31, 2022. Exclusions included liver disease, end-stage renal disease, a prescription for contraindicated medications, pregnancy in the previous year, or death within 60 days. Case patients received a Paxlovid prescription within \u00b15 days of the index date; control patients matched on age, sex, month, and region did not receive Paxlovid within \u00b15 days. Cases and controls were matched 1:2. Analysis was conducted separately for 3 age groups: 12-17 years, 18-49 years, and \u226550 years. PCC was defined as new conditions &amp;gt; 60 days after index date and prior to December 31, 2022. We calculated the relative risk (RR) of two overall PCC indicators (\u2265 1 or \u2265 2 conditions) and 45 individual conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among adults aged \u2265 50 years, the risks of overall and individual PCCs were generally lower among case- than control patients (RR for \u22651 condition=0.92, 95% CI=0.91-0.93; Figure 1). There was no overall difference in risk among adults 18-49; the RR of individual conditions varied (Figure 2). Among adolescents, the risks of overall and individual PCCs were higher among case than control patients (RR for \u22651 condition=1.07, 95% CI=1.02-1.12; Figure 3).Figure 1.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages \u226550 (N=564,303)Figure 2.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages 18-49 (N=292,818)Figure 3.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages 12-17 (N=17,178)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The results suggest that Paxlovid helps reduce occurrence of PCC in adults aged \u2265 50 years. Among younger adults and adolescents, associations were observed for only certain conditions. This may be due to a difference in baseline health in these age groups. Further investigation may help clarify whether Paxlovid provides benefits in reducing PCC in addition to severity of acute COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures<\/jats:title>\n                  <jats:p>Priti Patel, MD, MPH, Pfizer: Stocks\/Bonds<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad500.2468","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T02:17:17Z","timestamp":1701051437000},"source":"Crossref","is-referenced-by-count":2,"title":["1937. Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of Post-COVID Conditions among Children and Adults at High-Risk for Severe COVID-19, April 1 - December 31, 2022"],"prefix":"10.1093","volume":"10","author":[{"given":"Alexandra F","family":"Dalton","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baca","sequence":"additional","affiliation":[{"name":"GAP Solutions Inc. , Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Raykin","sequence":"additional","affiliation":[{"name":"CDC , Atlanta , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cria","family":"Perrine","sequence":"additional","affiliation":[{"name":"CDC , Atlanta , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tegan","family":"Boehmer","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Koumans","sequence":"additional","affiliation":[{"name":"CDC , Atlanta , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Patel","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Saydah","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,27]]},"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/Supplement_2\/ofad500.2468\/53773788\/ofad500.2468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/Supplement_2\/ofad500.2468\/53773788\/ofad500.2468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T02:17:18Z","timestamp":1701051438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad500.2468\/7448238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":0,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2023,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad500.2468","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,11,27]]},"article-number":"ofad500.2468"}}